{"id":12435,"date":"2003-12-01T05:55:51","date_gmt":"2003-12-01T05:55:51","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=12435"},"modified":"2014-05-27T10:31:52","modified_gmt":"2014-05-27T10:31:52","slug":"rituximab-plus-cde-for-hiv-related-non-hodgkins-lymphoma-nhl","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/12435","title":{"rendered":"Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Spina and colleagues from the Italian Cancer Centre presented results from a phase-II study (started in June 1998) of the monoclonal antibody rituximab given with CDE therapy plus HAART in 64 HIV-positive patients with NHL. Sixty-nine percent of patients had advanced stage (III-IV) disease and 52% had B symptoms. Median baseline CD4 count was 161 cells\/mm3 (range 3-691).<\/strong><\/p>\n<p>CDE was administered by continuous intravenous infusion for four days every four weeks (cyclophosphamide 187.5 mg\/m2\/day, doxorubicin 12.5 mg\/m2\/day and etoposide 60 mg\/m2\/day) and rituximab 375 mg\/m2 i.v. on day one of each cycle. HAART was given concomitantly with CT.<\/p>\n<p>Forty-five out of 64 patients (71%) achieved a complete remission (CR), 4\/64 (6%) had a partial remission and 15 patients progressed. Seven of the CRs have since relapsed and 44\/64 patients are still alive. Grade 3-4 neutropaenia, anaemia and thrombocytopaenia were observed in 78%, 36% and 25% of patients respectively. One quarter of the patients developed bacterial infections during neutropenia. The actuarial overall survival and time to treatment failure (TTF) at two years were 65% and 63% respectively.<\/p>\n<p>The study concluded that the combination of rituximab and CDE treated concomitantly with HAART is safe, feasible and active and that the clearance rate (71%) and TTF at two years (63%) are comparable to those observed in high grade NHL of the general population.<\/p>\n<p>Reference:<\/p>\n<p>Spina M, Simonelli C, Vaccher E et al. Rituximab and infusional cyclophosphamide, doxorubicin and etoposide (CDE) in combination with HAART: a safe and highly active regimen in HIV-related Non-Hodgkins Lymphoma (NHL). 9th EACS, Warsaw. 25-29 October 2003. Abstract F9\/1.<br \/>\n<a href=\"http:\/\/www.aegis.org\/conferences\/eacs\/2003\/44.html\">http:\/\/www.aegis.org\/conferences\/eacs\/2003\/44.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Spina and colleagues from the Italian Cancer Centre presented results from a phase-II study (started in June 1998) of the monoclonal antibody rituximab given with CDE therapy plus HAART in 64 HIV-positive patients with NHL. Sixty-nine &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3,18],"tags":[75],"class_list":["post-12435","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","category-cancer-and-hiv","tag-eacs-9th-2003"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=12435"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/12435\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=12435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=12435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=12435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}